Results 231 to 240 of about 415,260 (411)

TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk

Hepatology, EarlyView., 2022
The systematic approach in elucidating the gain‐of‐function (GOF) roles of TP53 mutations in early liver carcinogenesis. Unique downstream targets of TP53 L3 mutations were identified from chormatin immunoprecipitation sequencing in HCC cell lines, followed by a series of validation assays to substantiate the exclusive transcriptional regulations ...
Yin Kau Lam, Jianqing Yu, Hao Huang, Xiaofan Ding, Alissa M. Wong, Howard H. Leung, Anthony W. Chan, Kelvin K. Ng, Mingjing Xu, Xin Wang, Nathalie Wong   +10 more
wiley   +1 more source

Experience of BK Virus in Allogenic and Autologous Bone Marrow Transplantation:

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The BK virus is a member of the polyomavirus family. When the immune system is compromised, as in patients undergoing chemotherapy after hematopoietic stem cell and solid organ transplantation, the virus is reactivated leading to haemorrhagic cystitis ...
Ilhami BERBER, Mehmet Ali ERKURT, Emin KAYA, Irfan KUKU, Mustafa KOROGLU, Ilknur NIZAM   +5 more
doaj  

Nonmyeloablative Allogeneic Stem Cell Transplantation: Early Promise and Limitations [PDF]

, 2000
Nicole McCarthy, Michael R. Bishop
openalex   +1 more source

Granulocytic sarcoma after stem cell transplantation in a child with biphenotypic leukemia [PDF]

, 2009
Granulocytic sarcoma is an extramedullary tumor composed of leukemic blasts. Isolated granulocytic sarcoma has rarely been reported in children with leukemia undergoing allogeneic stem cell transplantation.
Meryem Albayrak, Nalan Akyürek, Suna Özhan Oktar, Türkiz Gürsel, Zühre Kaya, Ülker Koçak   +5 more
core  

Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study

Annals of Neurology, EarlyView.
Objective To compare clinical and radiological outcomes among relapsing multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT), alemtuzumab (ATZ), and ocrelizumab (OCR). Methods From a London (UK) hospital‐based observational cohort, modeled data were obtained from 621 relapsing–remitting multiple sclerosis ...
Paolo Antonio Muraro, Antonio Zito, Alessio Signori, Maria Pia Sormani, Eleonora Rigoni, Federica Pollidoro, Roberto Bergamaschi, Alice Mariottini, Omar Malik, Ashwini Nandoskar, Victoria Singh‐Curry, Varun Mehra, Majid Kazmi, Ian Gabriel, Eli Silber, Richard Nicholas, Antonio Scalfari   +16 more
wiley   +1 more source

Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

Hematological Oncology, Volume 40, Issue 5, Page 987-998, December 2022., 2022
Abstract The treatment scenario for newly‐diagnosed transplant‐ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors and/or immunomodulatory drugs +/− the monoclonal antibody Daratumumab are used for first‐line treatment, even if head‐to‐head comparisons are lacking.
Cirino Botta, Emilia Gigliotta, Bruno Paiva, Rita Anselmo, Marco Santoro, Paula Rodriguez Otero, Melania Carlisi, Concetta Conticello, Alessandra Romano, Antonio Giovanni Solimando, Claudio Cerchione, Matteo Da Vià, Niccolò Bolli, Pierpaolo Correale, Francesco Di Raimondo, Massimo Gentile, Jesus San Miguel, Sergio Siragusa   +17 more
wiley   +1 more source

Absence of Functional Autoantibodies Targeting Angiotensin II Receptor Type 1 and Endothelin‐1 Type A Receptor in Circulation and Purified IgG From Patients With Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is a rare but severe autoimmune disease characterized by immune dysregulation, fibrosis, and vasculopathy. Although previous studies have highlighted the presence of functional autoantibodies targeting the angiotensin II receptor type 1 (AT1) and endothelin‐1 type A receptor (ETAR), leading to autoantibody‐mediated ...
Wieke M. van Oostveen, Eva M. Hoekstra, E. W. Nivine Levarht, Ilana B. Kotliar, Thomas P. Sakmar, René E. M. Toes, Jeska K. de Vries‐Bouwstra, Laura H. Heitman, Cynthia M. Fehres   +8 more
wiley   +1 more source

NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma

Hematological Oncology, Volume 40, Issue 5, Page 864-875, December 2022., 2022
Abstract The role of macrophages (Mo) and their prognostic impact in diffuse large B‐cell lymphomas (DLBCL) remain controversial. By regulating the lipid metabolism, Liver‐X‐Receptors (LXRs) control Mo polarization/inflammatory response, and their pharmacological modulation is under clinical investigation to treat human cancers, including lymphomas ...
Maria Carmela Vegliante, Saveria Mazzara, Gian Maria Zaccaria, Simona De Summa, Flavia Esposito, Federica Melle, Giovanna Motta, Maria Rosaria Sapienza, Giuseppina Opinto, Giacomo Volpe, Antonella Bucci, Grazia Gargano, Anna Enjuanes, Valentina Tabanelli, Stefano Fiori, Carla Minoia, Felice Clemente, Antonio Negri, Alessandro Gulino, Gaia Morello, Anna Scattone, Alfredo F. Zito, Stefania Tommasi, Claudio Agostinelli, Umberto Vitolo, Annalisa Chiappella, Anna Maria Barbui, Enrico Derenzini, Pier Luigi Zinzani, Beatrice Casadei, Alfredo Rivas‐Delgado, Armando López‐Guillermo, Elias Campo, Antonio Moschetta, Attilio Guarini, Stefano A. Pileri, Sabino Ciavarella   +36 more
wiley   +1 more source

Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: When to stop prophylaxis?

Arthritis &Rheumatology, Accepted Article.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

Socioeconomic position and clinical outcomes in patients with myelodysplastic syndromes: A population‐based cohort study

Hematological Oncology, Volume 40, Issue 5, Page 1056-1066, December 2022., 2022
Abstract Low socioeconomic position (SEP) may be associated with adverse outcomes in patients with myelodysplastic syndromes (MDS) inherent to for example, delayed diagnosis or reduced treatment intensity, but firm evidence is limited. In this study, we examined the association between SEP and clinical outcomes.
Tine Bichel Lauritsen, Lene Sofie Granfeldt Østgård, Kirsten Grønbæk, Susanne Oksbjerg Dalton, Jan Maxwell Nørgaard   +4 more
wiley   +1 more source